Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Eight Patent Applications Related to RNAi: Sep 11, 2008

Premium
Title: RNA Interference Using a Universal Target
 
Number: 7,422,853
 
Filed: Oct. 6, 2003
 
Lead Inventor: Liwen Huang, Myriad Genetics
 
The invention provides “novel methods for manipulating levels of expression of gene products using RNA interference,” the patent’s abstract states. “The methods disclosed can be used to investigate gene function, to create disease-resistant organisms, and to treat disease.”
 
Specifically, the patent claims a method for altering gene expression by “providing a plurality of 10 or more target cell cultures each expressing a chimeric RNA transcript [with] a subject RNA operably linked to a universal target RNA, wherein at least 10 of the plurality of 10 or more target cell cultures express chimeric RNA transcripts with different subject RNAs, and wherein all of said plurality of 10 or more target cell cultures express chimeric RNA transcripts with the same universal target RNA.” The method then calls for “introducing into said plurality of 10 or more target cell cultures [an siRNA or shRNA targeting the] universal target RNA.”
 

 
Title: Nanoparticles Comprising RNA Ligands
 
Number: 20080213177
 
Filed: May 24, 2005 PCT Filed: May 24, 2005
 
Lead Inventor: Thomas William Rademacher, University College London
 
“Materials and methods are provided for making nanoparticles having a core including metal and/or semiconductor atoms, which core is covalently linked to a plurality of ligands comprising a RNA ligand,” the patent application’s abstract states. “The RNA ligands may include siRNA or miRNA. Also provided are uses of these nanoparticles in therapy and diagnosis.”
 

 
Title: Methods and Compositions for RNA Interference
 
Number: 20080213861
 
Filed: Aug. 20, 2007
 
Lead Inventor: Greg Hannon, Cold Spring Harbor Laboratory
 
The invention, the patent application’s abstract states, “provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double-stranded RNA, such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited.”
 

 
Title: Altering Regulation of Maize Lignin Biosynthesis Enzymes Via RNAi Technology
 
Number: 20080213871
 
Filed: Nov. 29, 2007
 
Inventor: Masomeh Sticklen, Michigan State University
 
The invention, according to the patent application’s abstract, “relates to compositions and methods for providing RNA interference vectors comprising maize lignin biosynthesis enzymes for altering lignin content of plants. Specifically, plants comprising RNAi maize lignin vectors for reducing or altering lignin content are provided for reducing pretreatment costs of biofuel production. Additionally, RNAi maize lignin vectors are provided for altering cellulose production in plants for reducing pretreatment costs of plant biomass processing by increasing amounts of fermentable sugars.”
 

 
Title: RNAi Agents Comprising Universal Nucleobases
 
Number: 20080213891
 
Filed: Aug. 6, 2007
 
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
 
According to the patent application’s abstract, “one aspect of the present invention relates to an oligonucleotide agent comprising at least one universal nucleobase. In certain embodiments, the universal nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the universal nucleobase is difluorotolyl. In certain embodiments, the oligonucleotide is [either] double-stranded [or] ... single-stranded.
 
“Another aspect of the … invention relates to a method of altering the expression level of a target in the presence of target sequence polymorphism,” the abstract adds. “In a preferred embodiment, the oligonucleotide agent alters the expression of different alleles of a gene. In another preferred embodiment, the oligonucleotide agent alters the expression level of two or more genes. In another embodiment, the oligonucleotide agent alters the expression level of a viral gene from different strains of the virus. In another embodiment, the oligonucleotide agent alters the expression level of genes from different species.”
 

 
Title: RNAi-Mediated Inhibition of Aquaporin 4 for the Treatment of IOP-Related Conditions
 
Number: 20080214486
 
Filed: Nov. 28, 2007
 
Lead Inventor: Jon Chatterton, Alcon
 
“RNA interference is provided for inhibition of aquaporin 4 in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma,” according to the patent application’s abstract.
 

 
Title: Triggered RNAi
 
Number: 20080214488
 
Filed: Feb. 29, 2008
 
Lead Inventor: Niles Pierce, California Institute of Technology
 
The invention, the patent application’s abstract states, “relates to methods and compositions for triggering RNAi. … The method comprises providing an initiator to a cell comprising a detection target and a silencing target gene, wherein the detection target is different from the silencing target gene; providing a first substrate monomer to the cell, wherein the first substrate monomer comprises a silencing target complement region that is substantially complementary to a portion of the silencing target gene, and an initiator complement region that is substantially complementary to a portion of the initiator; and providing a second substrate monomer to the cell, wherein the second substrate monomer comprises a silencing target region that is substantially complementary to the silencing target complement region; wherein binding of the detection target to the initiator initiates formation of an inactivator double-stranded RNA [that] silences the silencing target gene.”
 

 
Title: Aptamer-Mediated Intracellular Delivery of Oligonucleotides
 
Number: 20080214489
 
Filed: March 12, 2008
 
Lead Inventor: Anthony Keefe, Archemix
 
The patent application, its abstract states, claims “compositions and methods to mediate the intracellular and sub-cellular delivery of therapeutic, diagnostic, and imaging agents such as oligonucleotides. The compositions of the invention include nucleic acid conjugates comprising a delivery aptamer that is connected to an oligonucleotide. The delivery aptamer may be connected directly to the oligonucleotide, or may be connected indirectly to the oligonucleotide, such as through a linker. ... The methods of the invention are used to increase potency, or alter distribution, half-life, metabolic fate, toxicity and other characteristics.”
 

 
Title: Computational Method for Choosing Nucleotide Sequences to Specifically Silence Genes
 
Number: 20080215251
 
Filed: June 28, 2007
 
Inventor: David Selinger, Pioneer Hi-Bred
 
The patent application, its abstract states, claims “a method for identifying subsequences in a polynucleotide sequence for specifically silencing a target gene.
 
“The method is described for identifying sequences effective in silencing a target gene or a series of genes, but not others,” the abstract adds. “Subsequences can be identified and scored using comparisons based on percent sequence identity with respect to a target reference sequence and siRNA algorithm analysis. The resulting subsequences may be ranked based on score, percent sequence identity. The identification of subsequences may be performed using a sliding window to identify all subsequences of a set length within the sequence. A user interface may be provided for displaying the results to a user.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.